Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial

Xiaomei Leng, Fengxiao Zhang, Shanglong Yao, Xisheng Weng, Kaizhi Lu, Gouzhong Chen, Ming Huang, Yuguang Huang, Xiaofeng Zeng, Michael Hopp, Guodong Lu, Xiaomei Leng, Fengxiao Zhang, Shanglong Yao, Xisheng Weng, Kaizhi Lu, Gouzhong Chen, Ming Huang, Yuguang Huang, Xiaofeng Zeng, Michael Hopp, Guodong Lu

Abstract

Introduction: Prolonged-release oxycodone/naloxone (OXN PR), combining an opioid analgesic with selective blockade of enteric µ-opioid receptors, provided effective analgesia and improved bowel function in patients with moderate-to-severe pain and opioid-induced constipation in clinical trials predominantly conducted in Western countries. This double-blind randomized controlled trial investigated OXN PR (N = 116) versus prolonged-release oxycodone (OXY PR, N = 115) for 8 weeks at doses up to 50 mg/day in patients with moderate-to-severe, chronic, non-malignant musculoskeletal pain and opioid-induced constipation recruited in China.

Methods: A total of 234 patients at least 18 years of age with non-malignant musculoskeletal pain for more than 4 weeks that was moderate-to-severe in intensity and required round-the-clock opioid therapy were randomized (1:1) to OXN PR or OXY PR. The primary endpoint was bowel function using the Bowel Function Index (BFI). Secondary endpoints included safety, Brief Pain Inventory-Short Form (BPI-SF), use of analgesic and laxative rescue medication, and health-related quality of life (EQ-5D).

Results: While BFI scores were comparable at baseline, at week 8 improvements were greater with OXN PR vs OXY PR (least squares mean [LSM] difference (95% CI) - 9.1 (- 14.0, - 4.2); P < 0.001. From weeks 2 to 8, mean BFI scores were in the range of normal bowel function (≤ 28.8) with OXN PR but were in the range of constipation (> 28.8) at all timepoints with OXY PR. Analgesia with OXN PR was similar and non-inferior to OXY PR on the basis of modified BPI-SF average 24-h pain scores at week 8: LSM difference (95% CI) - 0.3 (- 0.5, - 0.1); P < 0.001. The most frequent treatment-related AEs were nausea (OXN PR 5% vs OXY PR 6%) and dizziness (4% vs 4%).

Conclusion: OXN PR provided clinically meaningful improvements in bowel function and effective analgesia in Chinese patients with moderate-to-severe musculoskeletal pain and pre-existing opioid-induced constipation.

Trial registration: ClinicalTrials.gov, identifier NCT01918098.

Keywords: Bowel function index; China; Musculoskeletal pain; Opioid-induced constipation; Pain; Prolonged-release oxycodone/naloxone.

Figures

Fig. 1
Fig. 1
Patient disposition. OXN PR prolonged-release oxycodone/naloxone, OXY PR prolonged-release oxycodone. Full analysis population comprised patients who received at least one dose of study medication and had at least one assessment during double-blind treatment; per protocol population comprised patients who received at least one dose of study medication and complied with the study protocol; safety population comprised patients who received at least one dose of double-blind study medication. *n = 138 due to not meeting constipation criteria and n = 3 due to inadequate analgesia with OXY PR 50 mg/day
Fig. 2
Fig. 2
Bowel Function Index Scores at each study visit (full analysis population). BFI Bowel Function Index, EOT end of study treatment, OXN PR prolonged-release oxycodone/naloxone, OXY PR prolonged-release oxycodone. Data are mean ± SD. Lower scores indicate better bowel function. *P ≤ 0.01 (two-sided t test). EOT data could be included from patients without data at all study timepoints. Hashed line represents the BFI threshold of 28.8 for normal bowel function in patients with pain (higher scores indicated worse constipation symptoms) [29]
Fig. 3
Fig. 3
Modified BPI-SF: average pain over the last 24 h (per protocol population). BPI-SF Brief Pain Inventory-Short Form, EOT end of study treatment, OXN PR prolonged-release oxycodone/naloxone, OXY PR prolonged-release oxycodone. Data are mean ± SD. Lower scores indicate less pain. *P ≤ 0.01 (two-sided t test) for non-inferiority with a margin of 0.8. BPI-SF scale: 0 = no pain to 10 = pain as bad as you can imagine. EOT data could be included from patients without data at all study timepoints

References

    1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333.
    1. Chen B, Li L, Donovan C, et al. Prevalence and characteristics of chronic body pain in China: a national study. Springerplus. 2016;5(1):938.
    1. Jackson T, Chen H, Iezzi T, Yee M, Chen F. Prevalence and correlates of chronic pain in a random population study of adults in Chongqing, China. Clin J Pain. 2014;30(4):346–352.
    1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11(11):1230–1239.
    1. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27(2):449–462.
    1. Wong WS, Fielding R. Prevalence and characteristics of chronic pain in the general population of Hong Kong. J Pain. 2011;12(2):236–245.
    1. de Sola H, Salazar A, Duenas M, Ojeda B, Failde I. Nationwide cross-sectional study of the impact of chronic pain on an individual’s employment: relationship with the family and the social support. BMJ Open. 2016;6(12):e012246.
    1. Epstein RS, Teagarden JR, Cimen A, Sostek M, Salimi T. When people with opioid-induced constipation speak: a patient survey. Adv Ther. 2017;34(3):725–731.
    1. Gannon B, Finn DP, O’Gorman D, Ruane N, McGuire BE. The cost of chronic pain: an analysis of a regional pain management service in Ireland. Pain Med. 2013;14(10):1518–1528.
    1. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–724.
    1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130.
    1. O’Brien T, Christrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3–19.
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain: United States, 2016. JAMA. 2016;315(15):1624–1645.
    1. Cheung CW, Choo CY, Kim Y-C, et al. Collaborative efforts may improve chronic non-cancer pain management in Asia: findings from a ten-country regional survey. J Pain Relief. 2016;5:1000225.
    1. Xia Z. Cancer pain management in China: current status and practice implications based on the ACHEON survey. J Pain Res. 2017;10:1943–1952.
    1. Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017;20(2S):S3–S92.
    1. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1–3):11–17.
    1. Sobczak M, Salaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014;49(1):24–45.
    1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1) Pain Med. 2009;10(1):35–42.
    1. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224–1232.
    1. Emmanuel A, Johnson M, McSkimming P, Dickerson S. Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pan Med. 2017;18:1932–1940.
    1. LoCasale RJ, Datto C, Margolis MK, Coyne KS. Satisfaction with therapy among patients with chronic non-cancer pain with opioid-induced constipation. J Manag Care Spec Pharm. 2016;22(3):246–253.
    1. Thibault K, Calvino B, Rivals I, et al. Molecular mechanisms underlying the enhanced analgesic effect of oxycodone compared to morphine in chemotherapy-induced neuropathic pain. PLoS One. 2014;9(3):e91297.
    1. Toyama K, Furuie H, Kuroda K, Ishizuka H. Pharmacokinetic bioequivalence studies of an extended-release oxycodone hydrochloride tablet in healthy Japanese subjects under fasting and fed conditions without an opioid antagonist. Drugs R D. 2017;17(3):363–370.
    1. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13(1):56–64.
    1. Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs. 2011;20(4):427–439.
    1. Morlion BJ, Mueller-Lissner SA, Vellucci R, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract. 2018;18(5):647–665.
    1. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–383.
    1. Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011;39(1):41–50.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9(12):1144–1154.
    1. Farrar JT, Young JP, Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158.
    1. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26(1):50–60.
    1. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10(4):531–543.
    1. Hwang CJ, Chung SS, Lee KY, et al. Analgesic efficacy and safety of prolonged-release oxycodone/naloxone in Korean patients with chronic pain from spinal disorders. Clin Orthop Surg. 2018;10(1):33–40.
    1. Lee KH, Kim TW, Kang JH, et al. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chin J Cancer. 2017;36(1):74.
    1. Jones GP, Tripathi SS. Oxycodone and naloxone combination: a 12-week follow-up in 20 patients shows effective analgesia without opioid-induced bowel dysfunction. Pain Ther. 2016;5(1):107–113.
    1. Koopmans G, Simpson K, De AJ, Lux EA, Wagemans M, Van MY. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. Curr Med Res Opin. 2014;30(11):2389–2396.
    1. Mehta V, Alaward S, Kuravinakop S, Nikolic S. Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives. Pain Physician. 2014;17(5):415–424.
    1. Poelaert J, Koopmans-Klein G, Dioh A, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015;37(4):784–792.
    1. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:12.
    1. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24(12):3503–3512.
    1. Dupoiron D, Stachowiak A, Loewenstein O, et al. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. Eur J Pain. 2017;21:1528–1537.
    1. Napp Pharmaceuticals. Targinact Summary of Product Characteristics 2017 [updated 13 January 2017. .
    1. Blagden M, Hafer J, Duerr H, Hopp M, Bosse B. Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two phase III trials. Neurogastroenterol Motil. 2014;26(12):1792–1801.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi